The designation follows Phase III HARMONi-GI1 results showing significantly improved overall survival versus durvalumab plus ...
Part of Phase III of the National Precision Medicine programme, the study will connect genomic and health data from nearly ...
The National Comprehensive Cancer Network® (NCCN®) announced the signing of a new agreement with the Viet Nam National Cancer ...
Abbott will commercialise Plosbrio®, a second brand of Ozempic® developed and manufactured by Novo, in Singapore and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results